Healthcare Industry News: Gambro
News Release - June 17, 2009
NxStage(R) Announces Medisystems(R) Bloodline Distribution Agreement with GambroLAWRENCE, Mass., June 17 (Healthcare Sales & Marketing Network) -- NxStage Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer of innovative dialysis products, today announced a 5-year distribution agreement in the United States between its subsidiary, Medisystems Corporation, and Gambro, pursuant to which Medisystems will supply blood tubing sets, including the ReadySet(R) and the Streamline(R) to Gambro. Gambro, in turn, will exclusively supply the bloodlines to certain customers for use with specific dialysis machines, subject to certain conditions.
Bloodlines are essential products used to deliver in-center dialysis treatments to patients with renal failure. This relationship builds upon NxStage's existing distribution relationships with long-standing partners Henry Schein, Inc. and B.Braun Medical, and will help to ensure that Medisystems' world class blood tubing set products are accessible to patients across the United States.
"We are pleased to offer Medisystems' bloodlines as part of our product portfolio for chronic dialysis," said Nick Mendez, President of Gambro Americas. "We believe Medisystems' products deliver leading quality, performance, and customer satisfaction. The Medisystems product line, particularly the Streamline technology, complements the unique value Gambro delivers to dialysis centers and patients with such novel technology as is incorporated into for instance Gambro's new Revaclear dialyzers. We look forward to a productive relationship with Medisystems."
"Gambro is clearly a world leader in hemodialysis technology and distribution," stated Jeffrey H. Burbank, Chief Executive Officer of NxStage Medical. "We believe the union of our innovation and product quality with Gambro's complementary technologies and distribution capabilities will further strengthen both companies' presence in the in-center dialysis products market."
Medisystems' latest generation blood tubing set is the Streamline. Streamline features an efficient and airless design intended to improve clinical and economic performance. Streamline is designed to reduce dialysate flow, dialyzer size, treatment time, minimize heparin and waste, and optimize dose delivery, as measured in Kt/V. Streamline also includes Medisystems' patented LockSite(R) needleless access ports, which eliminate the need for sharp needles or costlier guarded needles to be used with the tubing set during dialysis.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM ) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, changes relating to Gambro's, or customers' demand for Medisystems brand blood tubing sets, including Streamline, anticipated benefits of the Gambro distribution relationship, and other factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2009. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Source: NxStage Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.